Sage Therapeutics, Inc. SAGE Balance Sheet

Sage therapeutics, inc. (SAGE)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Dec'13
Assets
Current assets:
Cash and cash equivalents
199,444	126,705	259,181	166,185	342,295	190,943	253,123	325,830	557,555	306,235	134,916	133,450	145,460	168,517	320,078	189,003	299,680	186,753	204,877	224,234	113,162	127,766	136,727	49,127	8,066
Marketable securities
673,313	881,688	863,069	1,070,364	1,008,956	731,833	768,278	766,603	525,958	212,613	108,535	152,478	197,104	228,962	111,192	83,292	-	0	-	-	-	-	-	-	-
Prepaid expenses and other current assets
25,479	26,700	30,413	27,021	20,281	21,919	18,511	12,958	11,575	6,227	4,892	5,192	6,480	5,100	3,418	1,812	2,926	1,738	2,604	3,274	1,367	1,056	1,063	2,416	341
Receivable from collaborator
-	-	-	-	-	-	-	18,378	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets
898,236	1,035,093	1,152,663	1,263,570	1,371,532	944,695	1,039,912	1,123,769	1,095,088	525,075	248,343	291,120	349,044	402,579	434,688	274,107	302,606	188,491	207,481	227,508	114,529	128,822	137,790	51,543	8,407
Property and equipment, net
8,684	9,126	9,365	8,363	6,513	5,643	5,168	4,445	4,295	4,013	1,893	1,443	1,560	1,388	1,049	959	865	286	249	285	269	163	134	69	86
Restricted cash
2,367	2,367	2,367	2,367	2,367	2,367	1,919	1,269	1,269	849	849	849	564	564	564	564	39	39	39	39	39	39	39	39	39
Right-of-use operating asset
31,992	33,771	35,514	37,224	38,124	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term assets
3,694	3,793	3,818	4,023	4,378	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200	-	-	-	-	-	-	-
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	641	641	641	641	-	-	-
Total assets
944,973	1,084,150	1,203,727	1,315,547	1,422,914	952,705	1,046,999	1,129,483	1,100,652	529,937	251,085	293,412	351,168	404,531	436,301	275,630	303,510	189,016	208,410	228,473	115,478	129,665	137,963	51,651	8,532
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
7,910	15,266	5,041	12,431	13,556	34,036	5,879	8,338	8,350	9,350	13,030	6,042	8,230	12,817	5,237	5,957	4,540	5,159	3,246	5,195	2,782	2,429	2,157	1,862	1,988
Accrued expenses
52,180	86,618	78,127	58,912	47,651	51,994	48,647	39,581	29,522	42,601	36,807	26,239	23,652	22,352	17,093	12,382	11,430	10,148	6,404	5,164	5,522	4,687	2,853	2,069	327
Operating lease liability, current portion
10,270	10,244	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
-	-	7,788	7,610	7,169	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	641	641	641	641	-	-	-
Total current liabilities
70,360	112,128	90,956	78,953	68,376	86,030	54,526	47,919	37,872	51,951	49,837	32,281	31,882	35,169	22,330	18,339	15,970	15,307	10,291	11,000	8,945	7,757	5,010	3,931	2,315
Operating lease liability, net of current portion
24,951	26,848	31,360	33,309	34,528	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
456	519	340	410	476	3,704	3,968	3,801	3,504	2,511	1,196	827	840	845	234	82	40	14	15	22	23	23	34	40	44
Total liabilities
95,767	139,495	122,656	112,672	103,380	89,734	58,494	51,720	41,376	54,462	51,033	33,108	32,722	36,014	22,564	18,421	16,010	15,321	10,306	11,022	8,968	7,780	5,044	3,971	2,359
Commitments and contingencies (Note 5)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0
Redeemable convertible preferred stock (Series A, B and C), $0.0001 par value; no shares and 37,750,000 shares authorized at December 31, 2014 and 2013, respectively; no shares and 37,750,000 shares issued and outstanding at December 31, 2014 and 2013, respectively; liquidation preference of $0 and $40,663 at December 31, 2014 and 2013, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92,472	37,709
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued or outstanding at March 31, 2020 and December 31, 2019
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0
Common stock, $0.0001 par value per share; 120,000,000 shares authorized at March 31, 2020 and December 31, 2019; 51,920,852 and 51,880,227 shares issued at March 31, 2020 and December 31, 2019; 51,917,819 and 51,877,194 shares outstanding at March 31, 2020 and December 31, 2019
5	5	5	5	5	5	5	5	5	5	4	4	4	4	4	3	3	3	3	3	3	3	3	0	-
Treasury stock, at cost, 3,033 shares at March 31, 2020 and December 31, 2019
400	400	400	400	400	211	211	211	211	113	17	17	17	17	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
2,620,700	2,587,322	2,554,603	2,496,651	2,446,770	1,827,021	1,793,909	1,760,137	1,724,712	1,066,059	721,105	707,690	695,645	688,959	678,194	483,797	479,380	335,032	330,879	326,191	190,223	188,727	187,400	-	139
Accumulated deficit
-1,800,000	-1,643,567	-1,500,000	-1,300,000	-1,126,735	-963,329	-804,941	-682,023	-665,045	-590,447	-521,025	-447,306	-377,105	-320,327	-264,426	-226,630	-191,883	-161,340	-132,778	-108,743	-83,716	-66,845	-54,484	-44,792	-31,675
Accumulated other comprehensive gain (loss)
-792	1,295	1,777	1,575	-106	-515	-257	-145	-185	-29	-15	-67	-81	-102	-35	39	-	-	-	-	-	-	-	-	-
Total stockholders’ equity
849,206	944,655	1,081,071	1,202,875	1,319,534	862,971	988,505	1,077,763	1,059,276	475,475	200,052	260,304	318,446	368,517	413,737	257,209	287,500	173,695	198,104	217,451	106,510	121,885	132,919	-44,792	-31,536
Total liabilities and stockholders’ equity
944,973	1,084,150	1,203,727	1,315,547	1,422,914	952,705	1,046,999	1,129,483	1,100,652	529,937	251,085	293,412	351,168	404,531	436,301	275,630	303,510	189,016	208,410	228,473	115,478	129,665	137,963	51,651	8,532